Efficacy and Safety of SH T00660AA in Treatment of Endometriosis

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Oral Administration of SH T00660AA for the Treatment of Endometriosis Over 12 Weeks

The purpose of this study is to demonstrate safety and efficacy of SH T00660AA compared to placebo in the treatment of endometriosis

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Inclusion Criteria:

• Female patients with endometriosis-associated pelvic pain

Exclusion Criteria:

• Pregnant or lactating women
• history or suspicion of hormone dependent tumor
• therapy resistant endometriosis
• need for primary surgical treatment
• any other conditions which forbid the participation.